Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NMT1 | P30419 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850999 | 0.80 | KDM4E (0.79) | TDP1POLBTGM2NPC1RAB9A | |
| SCHEMBL455439 | 0.80 | TDP1 (0.70) | TDP1POLBTGM2NPC1RAB9A | |
| SCHEMBL1275920 | 0.80 | ALDH1A1 (0.70) | TDP1POLBNPC1RAB9AKDM4E | |
| SCHEMBL7921886 | 0.78 | MAPT (0.60) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL2093333 | 0.78 | TDP1 (0.67) | TDP1POLBTGM2NPC1RAB9A | |
| SCHEMBL61417 | 0.78 | TDP1 (1.00) | TDP1POLBNPC1RAB9AKDM4E | |
| Fluoride SCHEMBL11790965 | 0.78 | TDP1 (0.67) | TDP1POLBTGM2NPC1RAB9A | |
| SCHEMBL6358702 | 0.77 | MAPT (0.60) | POLBNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL2912453 | 0.77 | RAB9A (0.80) | TDP1POLBNPC1RAB9AKDM4E | |
| SCHEMBL81433 | 0.76 | KIF11 (0.88) | TDP1POLBTGM2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651879-B1 | ENANTIOMERICALLY PURE BINAPHTHOL DERIVATIVES AND METHOD FOR PREPARING THE SAME | AMINOLOGICS CO LTD (KR) | 2018-03-07 | — | — | EP | claimed |
| US-9198426-B2 | Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | claimed |
| US-20140012038-A1 | ENANTIOMERICALLY PURE BINAPHTHOL DERIVATIVES AND METHOD FOR PREPARING THE SAME | AMINOLOGICS CO., LTD. (KR) | 2014-01-09 | — | — | US | claimed |
| EP-2651879-A2 | ENANTIOMERICALLY PURE BINAPHTHOL DERIVATIVES AND METHOD FOR PREPARING THE SAME | Aminologics Co., Ltd (KR) | 2013-10-23 | — | — | EP | claimed |
| WO-2012081885-A2 | ENANTIOMERICALLY PURE BINAPHTHOL DERIVATIVES AND METHOD FOR PREPARING THE SAME | AMINOLUX, INC. (KR) | 2012-06-21 | — | — | WO | claimed |
| EP-2378880-A1 | USE OF 5-PYRIDIN-4YL(1,3)THIAZOLE FOR TREATING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AG (DE) | 2011-10-26 | — | — | EP | claimed |
| US-20100168185-A1 | Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER CORPSCIENCE AG (DE) | 2010-07-01 | — | — | US | claimed |
| WO-2010069494-A1 | USE OF 5-PYRIDIN-4YL(1,3)THIAZOLE FOR TREATING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-06-24 | — | — | WO | claimed |
| EP-2198710-A1 | Use of 5-pyridin-4yl-(1,3) thiazoles for combating phytopathogenic fungi | Bayer CropScience AG (DE) | 2010-06-23 | — | — | EP | claimed |
| US-9198426-B2 | Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| EP-1932841-B1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8415372-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2013-04-09 | — | — | US | disclosed |
| EP-2378880-A1 | USE OF 5-PYRIDIN-4YL(1,3)THIAZOLE FOR TREATING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AG (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20060205594-A1 | Heat-sensitive recording material | FUJI PHOTO FILM CO., LTD. | 2006-09-14 | — | — | US | disclosed |
| US-4775757-A | CARDIOTONIC AND RENAL VASODILATING AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-10-04 | — | — | US | disclosed |
| US-4065395-A | Aryl diurea-thickened greases | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4022799-A | DYEING, PRINTING OF NATURAL AND SYNTHETIC MATERIALS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-10 | — | — | US | disclosed |
| US-4001253-A | NAPHTHOLACTAM DYESTUFFS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
| US-3950347-A | NAPHTHOLACTAM DYESTUFFS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168185-A1 | Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | PIR, PNPO, PDXK | TDP1 1604/4885POLB 4343/4885TGM2 1102/4885 |
| US-20140012038-A1 | ENANTIOMERICALLY PURE BINAPHTHOL DERIVATIVES AND METHOD FOR PREPARING THE SAME | ALDH1A1, ALDH7A1, ALDH3A1 | TDP1 3302/4885POLB 1613/4885TGM2 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.